4/2
11:26 am
omer
Omeros: Making The Bull Case On Q4 Earnings, Ahead Of Key Q1 Commercial Updates [Seeking Alpha]
Low
Report
Omeros: Making The Bull Case On Q4 Earnings, Ahead Of Key Q1 Commercial Updates [Seeking Alpha]
4/1
03:57 am
omer
Omeros Corporation (OMER) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Omeros Corporation (OMER) Q4 2025 Earnings Call Transcript [Seeking Alpha]
3/31
06:16 pm
omer
Omeros Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Omeros Q4 Earnings Call Highlights [Yahoo! Finance]
3/31
04:02 pm
omer
Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results
High
Report
Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results
3/26
09:00 am
omer
Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026 [Yahoo! Finance]
Low
Report
Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026 [Yahoo! Finance]
3/26
08:45 am
omer
Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026
Low
Report
Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026
3/21
03:48 am
omer
Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment [Yahoo! Finance]
Medium
Report
Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment [Yahoo! Finance]
3/21
03:23 am
omer
Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment
Medium
Report
Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment
3/2
07:18 am
omer
Omeros: Yartemlea Can Own The Label And Still Split The Market [Seeking Alpha]
Low
Report
Omeros: Yartemlea Can Own The Label And Still Split The Market [Seeking Alpha]
2/17
08:45 am
omer
Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program
Low
Report
Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program
1/27
10:59 am
omer
Omeros (NASDAQ:OMER) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
Medium
Report
Omeros (NASDAQ:OMER) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
1/27
09:00 am
omer
Omeros Announces First Commercial Sales of YARTEMLEA®
Medium
Report
Omeros Announces First Commercial Sales of YARTEMLEA®
1/16
06:55 am
omer
Thrombotic Microangiopathy Global Clinical Trials Market Review Report 2025 [Yahoo! Finance]
Low
Report
Thrombotic Microangiopathy Global Clinical Trials Market Review Report 2025 [Yahoo! Finance]
1/8
08:23 am
omer
Omeros (NASDAQ:OMER) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
Medium
Report
Omeros (NASDAQ:OMER) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
1/8
08:23 am
omer
Omeros (NASDAQ:OMER) had its price target raised by analysts at HC Wainwright from $20.00 to $40.00. They now have a "buy" rating on the stock.
Medium
Report
Omeros (NASDAQ:OMER) had its price target raised by analysts at HC Wainwright from $20.00 to $40.00. They now have a "buy" rating on the stock.